Download Powerpoint - Blood Journal

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

page
1
page
2
Document related concepts
no text concepts found
Transcript 
Improving FCR immunochemotherapy in CLL
by Tadeusz Robak
Blood
Volume 115(3):437-438
January 21, 2010
©2010 by American Society of Hematology
Studies evaluating FCR alone and in combination with other agents in refractory/relapsed CLL.
NR indicates not reported; F, fludarabine; C, cyclophosphamide; R, rituximab; L, lumiliximab; A,
alemtuzumab; M, mitoxantrone; and m, months. *CR + CR unconfirmed.
Tadeusz Robak Blood 2010;115:437-438
©2010 by American Society of Hematology
Related documents